NasdaqGS:ABSIBiotechs
Absci (ABSI) Is Up 40.3% After Positive ABS-201 Data And Equity Raise Has The Bull Case Changed?
Earlier this week, Absci Corporation reported encouraging interim Phase 1 data for ABS-201 in androgenetic alopecia, showing a favorable safety profile across single ascending IV dose cohorts and an estimated half-life of at least 65 days, while also completing a US$100,000,003 follow-on equity offering of 13,495,277 common shares at US$7.41.
The early indication that ABS-201 might be dosed only two or three times over six months, combined with fresh funding to advance trials and pursue...